1 Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer 136, E359-386, doi:10.1002/ijc.29210 (2015).
2 Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 68, 394-424, doi:10.3322/caac.21492 (2018).
3 Chen, W. et al. Cancer statistics in China, 2015. CA: a cancer journal for clinicians 66, 115-132, doi:10.3322/caac.21338 (2016).
4 Hassanein, M. et al. The state of molecular biomarkers for the early detection of lung cancer. Cancer prevention research (Philadelphia, Pa.) 5, 992-1006, doi:10.1158/1940-6207.Capr-11-0441 (2012).
5 Zhou, J. et al. Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China. Asian Pacific journal of cancer prevention : APJCP 17, 965-971, doi:10.7314/apjcp.2016.17.3.965 (2016).
6 Sholl, L. M. et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. American journal of clinical pathology 133, 922-934, doi:10.1309/ajcpst1cthzs3psz (2010).
7 Dahabreh, I. J. et al. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 16, 291-303, doi:10.1158/1078-0432.Ccr-09-1660 (2010).
8 Penzel, R. et al. EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Archiv : an international journal of pathology 458, 95-98, doi:10.1007/s00428-010-1000-y (2011).
9 Zhou, Y. C. et al. [Analysis of EGFR mutation and clinical features of lung cancer in Yunnan]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 42, 729-734, doi:10.3760/cma.j.cn112152-20200313-00201 (2020).
10 Coco, S. et al. Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine. Current drug targets 16, 47-59, doi:10.2174/1389450116666141210094640 (2015).
11 Travis, W. D. et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 10, 1243-1260, doi:10.1097/jto.0000000000000630 (2015).
12 Dajac, J., Kamdar, J., Moats, A. & Nguyen, B. To Screen or not to Screen: Low Dose Computed Tomography in Comparison to Chest Radiography or Usual Care in Reducing Morbidity and Mortality from Lung Cancer. Cureus 8, e589, doi:10.7759/cureus.589 (2016).
13 Won, J. K. et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology 26, 348-354, doi:10.1093/annonc/mdu530 (2015).
14 Roskoski, R., Jr. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacological research 87, 42-59, doi:10.1016/j.phrs.2014.06.001 (2014).
15 Nakata, A. et al. Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Scientific reports 5, 13076, doi:10.1038/srep13076 (2015).
16 Gazzeri, S. [Nuclear EGFR: a new mode of oncogenic signalling in cancer]. Biologie aujourd'hui 212, 27-33, doi:10.1051/jbio/2018016 (2018).
17 Graham, R. P. et al. Worldwide Frequency of Commonly Detected EGFR Mutations. Archives of pathology & laboratory medicine 142, 163-167, doi:10.5858/arpa.2016-0579-CP (2018).
18 Shi, Y. et al. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study. PLoS One 10, e0143515, doi:10.1371/journal.pone.0143515 (2015).
19 Shi, Y. et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 9, 154-162, doi:10.1097/jto.0000000000000033 (2014).
20 Liam, C. K., Wahid, M. I., Rajadurai, P., Cheah, Y. K. & Ng, T. S. Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 8, 766-772, doi:10.1097/JTO.0b013e31828b5228 (2013).
21 Lee, S. H. et al. Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey. Journal of pathology and translational medicine 49, 481-488, doi:10.4132/jptm.2015.09.14 (2015).
22 Ma, Y. et al. Oncogenic Genetic Alterations in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. Cancer management and research 12, 10861-10874, doi:10.2147/cmar.S266069 (2020).
23 Yohe, S. & Thyagarajan, B. Review of Clinical Next-Generation Sequencing. Archives of pathology & laboratory medicine 141, 1544-1557, doi:10.5858/arpa.2016-0501-RA (2017).
24 Morganti, S. et al. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Advances in experimental medicine and biology 1168, 9-30, doi:10.1007/978-3-030-24100-1_2 (2019).
25 Chen, M. & Zhao, H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Human genomics 13, 34, doi:10.1186/s40246-019-0220-8 (2019).
26 Thomas, A., Rajan, A., Lopez-Chavez, A., Wang, Y. & Giaccone, G. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Ann Oncol 24, 577-585, doi:10.1093/annonc/mds478 (2013).
27 Masago, K. et al. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC cancer 15, 908, doi:10.1186/s12885-015-1925-2 (2015).
28 Rangachari, D. et al. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer treatment communications 4, 174-181, doi:10.1016/j.ctrc.2015.10.004 (2015).
29 Shao, D. et al. A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. Scientific reports 6, 22338, doi:10.1038/srep22338 (2016).
30 Tan, A. C. et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer 139, 207-215, doi:10.1016/j.lungcan.2019.11.022 (2020).
31 Xuan, J., Yu, Y., Qing, T., Guo, L. & Shi, L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 340, 284-295, doi:10.1016/j.canlet.2012.11.025 (2013).
32 Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine 366, 883-892, doi:10.1056/NEJMoa1113205 (2012).
33 Crowley, E., Di Nicolantonio, F., Loupakis, F. & Bardelli, A. Liquid biopsy: monitoring cancer-genetics in the blood. Nature reviews. Clinical oncology 10, 472-484, doi:10.1038/nrclinonc.2013.110 (2013).
34 Pantel, K. & Alix-Panabières, C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer research 73, 6384-6388, doi:10.1158/0008-5472.Can-13-2030 (2013).
35 Kimura, H. et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12, 3915-3921, doi:10.1158/1078-0432.Ccr-05-2324 (2006).
36 Liang, C. et al. Detection of Rare Mutations in EGFR-ARMS-PCR- Negative Lung Adenocarcinoma by Sanger Sequencing. Yonsei medical journal 59, 13-19, doi:10.3349/ymj.2018.59.1.13 (2018).
37 Liu, J., Zhao, R., Zhang, J. & Zhang, J. ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens. J Cancer Res Clin Oncol 141, 221-227, doi:10.1007/s00432-014-1807-z (2015).
38 Kruglyak, K. M., Lin, E. & Ong, F. S. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. Advances in experimental medicine and biology 890, 123-136, doi:10.1007/978-3-319-24932-2_7 (2016).